Physician profile
Kerry L Anders
NPI 1699736538
$5,049.03
in general payments reported to CMS, 2019-2025
32 companies · $355 in 2025
The $355 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,869 · 2020: $1,420 · 2021: $589 · 2022: $348 · 2023: $195 · 2024: $272 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $822.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $600.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $453.95 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $447.17 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $436.43 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $419.00 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $332.66 | 2019-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $314.84 | 2019-2025 | Gardasil 9, Capvaxive |
| Lilly USA, LLC | $284.73 | 2019-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $249.69 | 2019-2024 | Zoryve, Livalo, Seglentis |
| Pfizer INC. | $234.53 | 2019-2025 | |
| Esperion Therapeutics, INC. | $172.09 | 2020-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.52 | 2019-2025 | Jardiance, Synjardy |
| Avanir Pharmaceuticals, INC. | $128.73 | 2019-2021 | |
| Eisai INC. | $122.96 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $109.88 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $75.08 | 2019-2020 | |
| Abbvie INC. | $72.93 | 2021-2024 | |
| Amarin Pharma, INC. | $59.80 | 2019-2020 | |
| Inspire Medical Systems, INC. | $55.29 | 2025 | Inspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.41 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $48.18 | 2019-2021 | |
| Ibsa Pharma INC. | $37.59 | 2024-2025 | Tirosint, Licart, Flector |
| Glaxosmithkline, LLC. | $30.87 | 2019-2020 | |
| Insulet Corporation | $23.26 | 2025 | Omnipod |
| Biohaven Pharmaceuticals, INC. | $17.44 | 2021 | |
| Adlon Therapeutics L.P. | $16.19 | 2020 | |
| Assertio Therapeutics, INC. | $15.60 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.26 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.87 | 2025 | Caplyta |
| Astellas Pharma US INC | $14.31 | 2020 | |
| Horizon Therapeutics Plc | $13.95 | 2019 | |
| Shire North American Group INC | $12.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerry Anders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.